US Head and Neck Cancer Drugs Market Analysis

US Head and Neck Cancer Drugs Market Analysis


$ 3999

US Head and Neck Cancer Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Key drivers of the head and neck cancer drugs market in the USA include the increasing incidence of head and neck cancer, advancements in treatment options, rising demand for personalized medicine, and supportive government initiatives. Global Companies in Head and Neck Cancer Drugs Market are Bristol Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Sanofi, Roche Holding AG, Takeda Pharmaceutical Company Limited, Bayer AG, AbbVie Inc. and Eisai Co., Ltd.

ID: IN10USPH294 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Dr. Netal Patel

Buy Now

US Head and Neck Cancer Drugs Market Analysis Summary

US Head and Neck Cancer Drugs Market is valued at around $834.2 Mn in 2022 and is projected to reach $1485.5 Mn by 2030, exhibiting a CAGR of 7.48% during the forecast period 2023-2030.

Head and neck cancer is the seventh most common cancer in the world, with 1.1 M new diagnoses reported annually. Squamous cell carcinoma represents more than 90% of all head and neck cancers. Key drivers of the head and neck cancer drugs market in the USA include the increasing incidence of head and neck cancer, advancements in treatment options, rising demand for personalized medicine, and supportive government initiatives. Global Companies in Head and Neck Cancer Drugs Market are Bristol Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Sanofi, Roche Holding AG, Takeda Pharmaceutical Company Limited, Bayer AG, AbbVie Inc. and Eisai Co., Ltd.

Market Dynamics

Market Growth Drivers

  1. Increasing incidence and prevalence: The rising global incidence of head and neck cancer is a major market driver. Tobacco and alcohol usage, human papillomavirus (HPV) infection, and occupational exposure to particular dangers all contribute to the rising prevalence
  2. Treatment advancements: The discovery of targeted treatments, immunotherapies, and combination therapies has expanded treatment options for patients with head & neck cancer, resulting in improved outcomes and boosting market growth
  3. Supportive government initiatives: Government initiatives and financing for cancer research, early detection, and treatment programs have all contributed significantly to the growth of the head and neck cancer medications market
  4. Technological advancements: Advances in diagnostic approaches, such as molecular profiling and imaging modalities, have enhanced the early identification and diagnosis of head and neck cancer, adding to market expansion

Market Restraints

  1. High treatment costs: The cost of treating head and neck cancer, including medications, surgery, radiation therapy, and supportive care, can be prohibitively expensive, limiting access to modern therapies and impacting market growth
  2. Adverse effects and toxicity: Some medicines used to treat head and neck cancer can have serious side effects and toxicity, limiting their use and negatively impacting patient compliance
  3. Therapy resistance: Some patients may acquire resistance to specific treatments over time, resulting in treatment failure and the need for new therapeutic techniques
  4. Clinical trial recruitment challenges: Clinical trials for head and neck cancer medications can be difficult to conduct due to the disease's complexity, patient heterogeneity, and tight inclusion criteria, all of which affect the rate of drug development

Competitive Landscape

Key Players

  • Bristol Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Sanofi
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • AbbVie Inc.
  • Eisai Co., Ltd.

Developments in the Head and Neck Cancer Drugs Market

  • At ASCO 2023, Transgene and NEC will present new data on TG4050, an individualized cancer vaccine that induces specific immune responses against head and neck cancer.
  • Systimmune is now in Phase II clinical trials with Izalontamabis for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Head and Neck Cancer Drugs Market Segmentation

By Drug Class

  • Chemotherapy Drugs
  • Targeted Therapies
  • Immunotherapies
  • Supportive Care Medications

By Distribution Channel

  • Hospitals
  • Speciality Clinics
  • Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up